Should levodopa dose be reduced when switched to stalevo? - Wikidata - wikimedia - TriplyDB

Should levodopa dose be reduced when switched to stalevo?

Should levodopa dose be reduced when switched to stalevo?

http://www.wikidata.org/entity/Q46794730

about

Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson's disease Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Levodopa/carbidopa/entacapone in Parkinson's disease.

P2860

Q34041790-B97C1ACE-B667-4D55-910B-0BD4C38D05F6 Q37979869-2A7931EE-8093-4983-9D51-3C9D8C3D1117 Q45934197-97DB1902-0F70-424C-A171-063609FC557A

P2860

Should levodopa dose be reduced when switched to stalevo?

http://www.wikidata.org/entity/Q46794730

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh-hant

name

Should levodopa dose be reduced when switched to stalevo?

@en

Should levodopa dose be reduced when switched to stalevo?

@nl

type

label

Should levodopa dose be reduced when switched to stalevo?

@en

Should levodopa dose be reduced when switched to stalevo?

@nl

prefLabel

Should levodopa dose be reduced when switched to stalevo?

@en

Should levodopa dose be reduced when switched to stalevo?

@nl

P1433

Q46794730-29BBACE7-823D-4FDC-B77F-35381FDB9397

P1476

Q46794730-73D53980-DE55-4C03-AF24-DA13F38C4D73

P2093

Q46794730-05052689-30DE-4EEF-AD2F-DC8792651F7D

Q46794730-3322DF57-A648-49E0-9483-5164D77C9AED

Q46794730-59D47243-8E97-4567-A85A-250ADDC75939

Q46794730-D3B11E5E-EE30-412F-B37C-D9D901D2B0D2

P2860

Q46794730-06A93676-C789-47A3-B103-D84E9956EA54

Q46794730-33DCA460-7D9C-47AC-9FE9-6872C856E90E

Q46794730-5195407F-C2F6-4EC8-9402-BB3E977AFAF0

Q46794730-629564BD-87E1-481D-91F6-FC3D45E158BB

Q46794730-712E9478-AA17-4084-96DE-D9EBBB170F83

Q46794730-7EE74A36-850A-4853-9369-7DF96845285D

Q46794730-A35BDD77-3352-425F-808A-D60A7E4A3D20

Q46794730-A56EDEB8-9300-4698-8C00-D5B5715BD334

Q46794730-AA381517-9C26-4395-BF3D-E60F60862AA0

Q46794730-C4BC9C55-8227-4F79-AAFE-6A9316469115

P304

Q46794730-2B283880-8986-41C3-9493-732FF4FBA30F

P31

Q46794730-3800010F-ECE4-49BD-A122-8A4A1954AA72

P356

Q46794730-B18E81EF-F34E-426B-AA58-CD246276C359

P433

Q46794730-CC2279CF-CAFE-4439-A97B-07167D0A2D3B

P478

Q46794730-E5DC3DFF-A17D-496E-BF56-F4C05B7CFCEE

P577

Q46794730-1E7B762B-8B80-4098-92C5-3FE85B838957

P5875

Q46794730-F6B9CE9E-E502-40DB-A32F-682A6DD8C898

P698

Q46794730-20C6625B-9115-44F9-9A2F-2EA950F0BFBE

P921

Q46794730-67C7CA6B-9400-4FFA-A3F2-23B2B03FB39E

P356

J.1468-1331.2007.02047.X

P1433

European Journal of Neurology

P1476

Should levodopa dose be reduced when switched to stalevo?

@en

P2093

B Hernández

http://www.w3.org/2001/XMLSchema#string

G Linazasoro

http://www.w3.org/2001/XMLSchema#string

J Kulisevsky

http://www.w3.org/2001/XMLSchema#string

Spanish Stalevo Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Health related quality of life in Parkinson's disease: a systematic review of disease specific instruments

Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement.

What contributes to quality of life in patients with Parkinson's disease?

Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study

Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease.

Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations.

Good enough: a primer on the analysis and interpretation of noninferiority trials.

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients.

Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study.

P304

257-261

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1468-1331.2007.02047.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5636880

http://www.w3.org/2001/XMLSchema#string

P698

18215153

http://www.w3.org/2001/XMLSchema#string

P921